INVICTUS ANNOUNCES TERMINATION OF THE PREVIOUSLY ANNOUNCED BINDING LETTER OF INTENT WITH UNIFIED CANNABIS CORP.
Vancouver, B.C., Jan. 03, 2020 (GLOBE NEWSWIRE) — Vancouver, BC, January 3, 2020 – INVICTUS MD STRATEGIES CORP. (“Invictus” or the “Company”) (TSXV: GENE; OTCQX: IVITF; FRA: 8IS2) further to the Company’s news release dated December 16, 2019, the Company has terminated the binding letter of intent with Unified Cannabis Corp. of Calgary, Alberta in respect of the proposed $5.7 million convertible debenture financing. For more information, please visit www.invictus-md.com. Marc RipaInterim Chief Executive Officer Investor Relations 1-844-800-6086E-Mail: firstname.lastname@example.org Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. About Invictus Invictus is a global cannabis company with a focus on the Canadian cannabis space, offering a selection of products under a wide range of cannabinoid profiles that fit the demand of the Company’s medical clients and retail customers. The Company’s integrated sales approach is defined by five pillars of distribution including medical, adult-use, international, Licensed Producer to Licensed Producer and sales to provinces. To meet growing demand, Invictus is expanding its cultivation footprint with two cannabis production facilities licensed under the Cannabis Act, which replaced the Access to Cannabis for Medical Purposes Regulations in Canada. Invictus’ wholly-owned subsidiary Acreage Pharms Ltd.’s (“Acreage”) Phase I and Phase II facilities are in full production. Acreage is awaiting the amendment to their license from Health Canada to include the Phase III facility. AB Laboratories Inc., a company which is a 50% owned subsidiary of Invictus has completed its Phase II expansion and received its amended license from Health Canada. Another of Invictus’ wholly owned subsidiaries, 2015059 Alberta Ltd. (dba Leaf Wise), continues to connect medical clients to physicians for medical cannabis and to Invictus’ fully licensed cannabis producers under the Cannabis Act. Invictus is targeting up to 50 percent of production to medical cannabis. Invictus drives sustainable long-term shareholder value by continuing to develop Invictus’ Canadian production of medical and recreational cannabis products. For more information visit www.invictus-md.com.Kathy Love
Invictus MD Strategies Corp.